This month, MassHealth announced it would cease covering the medication, a move that will impact 22,000 Massachusetts residents but save the state an expected $15 million per year
Trulicity (dulaglutide) and Ozempic (semaglutide) are both medications used to treat type 2 diabetes, and they belong to the same class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Recipients are responsible for compliance with all applicable institutional, state, and federal regulations
If you experience a suspected side effect from any medicine or supplement, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Together, they target the three biggest obstacles to successful long-term weight management with GLP-1 medications: efficacy, tolerability, and body composition
N-terminal RIA